https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19297
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADRifampicin may induce P-gp and CYP450 and decrease the plasma concentration of Sofosbuvir / Velpatasvir / Voxilaprevir.
Possible decrease of clinical efficacy.
–
–
–
Contraindicated. Use alternative.
–
–
–
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
AUC |
Cmax |
3379 | 3379 |
---|---|
17/12/12 | 0/12/24 |
- | - |
400/100/100 mg * | 0/100/100 mg * |
x 1 | x 1 |
- 72%/- 82%/- 73% † | NA/+ 46%/+ 691% |
- 77%/- 71%/- 9% † | NA/+ 28%/+ 1010% |
3379 | 3379 |
---|---|
17/12/12 | 0/12/24 |
- | |
600 mg | 600 mg |
QD | x 1 |
Ref #3379 : * Administered separately in different clinical trials.
† GS-331007: AUC -5% and Cmax + 23%.
Voxilaprevir concentrations may increase with a single dose of rifampin, but decrease with multiple doses of rifampin.